ONECUT2高表达介导胃癌复发患者5-FU化疗耐药

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (3577 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：探究One cut结构域家族成员2（ONECUT2）是否可以作为对5-FU耐药的胃癌复发患者的治疗靶点。方法：利用癌症基因组图谱（TCGA）数据库分析ONECUT2基因在胃癌患者及胃癌复发患者的表达情况。利用基因集富集分析（GSEA）评估TCGA数据库中ONECUT2表达量与药物代谢相关生物学过程的相关性。利用CCK-8细胞毒性实验评估胃癌细胞敲低或过表达ONECUT2对5-FU的耐药情况。分析30例胃癌术后复发患者ONECUT2表达量与5-FU治疗效果的相关性。结果： TCGA数据库分析显示，在经受过化疗且复发的胃癌患者中，ONECUT2高表达的患者无病间隔期（disease-free interval,DFI）更短。GSEA分析结果表明，ONECUT2高表达与异生药物代谢通路呈正相关，这提示可能与胃癌患者的耐药相关。体外实验中，敲低ONECUT2降低胃癌细胞对5-FU的半数抑制浓度（IC50）值；反之，过表达ONECUT2增加细胞对5-FU的IC50值。30例胃癌复发患者对5-FU的药物敏感性与ONECUT2表达量相关。结论：胃癌复发患者的ONECUT2表达量更高，ONECUT2高表达与胃癌复发患者的5-FU耐药相关，可能是潜在的治疗靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱海峰1
	陈述2
	龙卫国3
	王旭4

关键词 ： One cut结构域家族成员2font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 胃癌复发font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 5-FU耐药font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, GSEAfont-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 细胞毒性font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 半数抑制浓度

Abstract： Objective： To explore whether one cut domain family member 2 (ONECUT2) transcription factor could be a therapeutic target for 5-FU resistant gastric cancer (GC) relapsed patients. Methods: The Cancer Genome Atlas (TCGA) database was used to analyze the expression level of ONECUT2 in GC patients and GC relapsed patients. Gene set enrichment analyses (GSEA) were performed using STAD patients from TCGA to explore the correlation between ONECUT2 and biological processes related to drug metabolism. CCK-8 cytotoxic assays were performed to evaluate the role of ONECUT2 knockdown or overexpression on 5-FU resistance in gastric cancer cell lines. 30 relapsed GC patients with previously resected tumor samples were recruited to analyze the correlation between ONECUT2 expression level and 5-FU treatment efficacy. Results: According to the results of TCGA data analysis, in GC patients with chemotherapeutic treatment and cancer reoccurrence events, higher ONECUT2 level contributed to shorter disease-free interval. GSEA results suggested that upregulated ONECUT2 was positively correlated with xenobiotic drug metabolism, and which was related to drug resistance in GC patients. ONECUT2 knockdown reduced IC50 value of 5-FU in GC cells in vitro; on the contrast, ONECUT2 overexpression increased IC50 value of 5-FU in GC cells in vitro. The sensitivity of 5-FU treatment was negatively correlated with ONECUT2 mRNA level of tumor samples derived from 30 GC patients who relapsed after surgical resection. Conclusion: Relapsed GC patients had a higher expression of ONECUT2, and higher ONECUT2 expression level was positively related to 5-FU resistance in relapsed GC patients. These results provided a potential therapeutic target for GC treatment.

Key words：

收稿日期: 2023-09-03

基金资助: 江苏省自然科学基金面上项目（BK20211124）

作者简介: 朱海峰（1973—），男，副主任医师，主要从事肿瘤化疗耐受相关研究，E-mail： zhfzjn0511@163.com

引用本文:

朱海峰1，陈述2，龙卫国3，王旭4. ONECUT2高表达介导胃癌复发患者5-FU化疗耐药[J]. 江苏大学学报:医学版, 2024, 24(01): 19-24. ZHU Haifeng1, CHEN Shu2, LONG Weiguo3, WANG Xu4. High expression of ONECUT2 mediates 5-FU chemotherapy resistance in patients with recurrent gastric cancer. Journal of Jiangsu University(Medicine Edition), 2024, 24(01): 19-24.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2024/V24/I01/19

［1］Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.

［2］Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies［J］. Cancer Metastasis Rev, 2020, 39(4): 1179-1203.

［3］卞慧琴, 谷雨, 陈瑾楠, 等. URI在胃癌组织的表达及对顺铂诱导的胃癌细胞凋亡的影响［J］. 江苏大学学报（医学版）, 2018, 28(5): 369-375.

［4］李先敏, 练炼, 慎晓明. 外周血中DPD mRNA和TS mRNA表达对含卡培他滨方案治疗进展期胃癌的疗效预测［J］. 江苏大学学报（医学版）, 2019, 29(3): 264-268.

［5］Jacquemin P, Lannoy VJ, Rousseau GG, et al. OC2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor6［J］. J Biol Chem, 1999, 274(5): 2665-2671.

［6］Shen M, Dong C, Ruan X, et al. Chemotherapyinduced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2［J］. Cancer Res, 2019, 79(14): 3608-3621.

［7］Shen C, Wang J, Xu Z, et al. ONECUT2 which is targeted by hsamiR15a5p enhances stemness maintenance of gastric cancer stem cells［J］. Exp Biol Med (Maywood), 2021, 246(24): 2645-2659.

［8］Ma Q, Wu K, Li H, et al. ONECUT2 overexpression promotes RASdriven lung adenocarcinoma progression［J］. Sci Rep, 2019, 9(1): 20021.

［9］Guo H, Ci X, Ahmed M, et al. ONECUT2 is a driver of neuroendocrine prostate cancer［J］. Nat Commun, 2019, 10(1): 278.

［10］Chen J, Chen J, Sun B, et al. ONECUT2 accelerates tumor proliferation through activating ROCK1 expression in gastric cancer［J］. Cancer Manag Res, 2020, 12: 6113-6121.

［11］Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform［J］. Nat Biotechnol, 2020, 38(6): 675-678.

［12］Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer［J］. Cancer Commun (Lond), 2019, 39(1): 10.

［13］Jiang Z, Tai Q, Xie X, et al. EIF4A3induced circ_0084615 contributes to the progression of colorectal cancer via miR599/ONECUT2 pathway［J］. J Exp Clin Cancer Res, 2021, 40(1): 227.

［14］Schlesinger Y, YosefovLevi O, KolodkinGal D, et al. Singlecell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells′ heterogeneity［J］. Nat Commun, 2020, 11(1): 4516.

［15］Mirja R, Sungyong Y, Julie Y, et al. ONECUT2 is a key node and therapeutic target in lethal prostate cancer［J］. Cancer Discov, 2019, 9(1): OF12.

［16］Nebert DW. Role of genetics and drug metabolism in human cancer risk［J］. Mutat Res, 1991, 247(2): 267-281.

［17］Stipp MC, Acco A. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review［J］. Cancer Chemother Pharmacol, 2021, 87(3): 295-309.

［18］TvedenNyborg P, Bergmann TK, Jessen N, et al. BCPT policy for experimental and clinical studies［J］. Basic Clin Pharmacol Toxicol, 2021, 128(1): 4-8.

［19］Halasa M, Luszczki JJ, DmoszynskaGraniczka M, et al. Antagonistic interaction between histone deacetylase inhibitor: cambinol and cisplatin—an isobolographic analysis in breast cancer in vitro models［J］. Int J Mol Sci, 2021, 22(16): 8573.

［20］Kim HJ, Gong MK, Yoon CY, et al. Synergistic antitumor effects of combined treatment with HSP90 inhibitor and PI3K/mTOR dual inhibitor in cisplatinresistant human bladder cancer cells［J］. Yonsei Med J, 2020, 61(7): 587-596.

［21］Sun CY, Nie J, Huang JP, et al. Targeting STAT3 inhibition to reverse cisplatin resistance［J］. Biomed Pharmacother, 2019, 117: 109135.

［22］Zhao Y, Feng X, Chen Y, et al. 5fluorouracil enhances the antitumor activity of the glutaminase inhibitor CB839 against PIK3CAmutant colorectal cancers［J］. Cancer Res, 2020, 80(21): 4815-4827.

［23］Zhang YH, Luo DD, Wan SB, et al. S1PR2 inhibitors potently reverse 5FU resistance by downregulating DPD expression in colorectal cancer［J］. Pharmacol Res, 2020, 155: 104717.